GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Beneish M-Score

NeoGenomics (NeoGenomics) Beneish M-Score

: -2.66 (As of Today)
View and export this data going back to 1996. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.66 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for NeoGenomics's Beneish M-Score or its related term are showing as below:

NEO' s Beneish M-Score Range Over the Past 10 Years
Min: -2.66   Med: -2.55   Max: 1.17
Current: -2.66

During the past 13 years, the highest Beneish M-Score of NeoGenomics was 1.17. The lowest was -2.66. And the median was -2.55.


NeoGenomics Beneish M-Score Historical Data

The historical data trend for NeoGenomics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.37 -2.37 -2.64 -2.64 -2.66

NeoGenomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.64 -2.62 -2.62 -2.55 -2.66

Competitive Comparison

For the Diagnostics & Research subindustry, NeoGenomics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics Beneish M-Score Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Beneish M-Score falls into.



NeoGenomics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of NeoGenomics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9444+0.528 * 0.8916+0.404 * 0.9957+0.892 * 1.1607+0.115 * 0.9149
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8706+4.679 * -0.04495-0.327 * 1.0472
=-2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $131.2 Mil.
Revenue was 155.552 + 151.954 + 146.917 + 137.22 = $591.6 Mil.
Gross Profit was 67.588 + 62.311 + 59.891 + 54.814 = $244.6 Mil.
Total Current Assets was $596.8 Mil.
Total Assets was $1,681.2 Mil.
Property, Plant and Equipment(Net PPE) was $183.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $72.6 Mil.
Selling, General, & Admin. Expense(SGA) was $313.9 Mil.
Total Current Liabilities was $96.3 Mil.
Long-Term Debt & Capital Lease Obligation was $606.1 Mil.
Net Income was -14.326 + -18.516 + -24.331 + -30.795 = $-88.0 Mil.
Non Operating Income was -1.081 + -2.221 + -2.344 + -4.798 = $-10.4 Mil.
Cash Flow from Operations was 17.784 + -5.497 + -1.548 + -12.692 = $-2.0 Mil.
Total Receivables was $119.7 Mil.
Revenue was 138.705 + 128.782 + 125.072 + 117.169 = $509.7 Mil.
Gross Profit was 56.825 + 48.893 + 43.946 + 38.232 = $187.9 Mil.
Total Current Assets was $605.3 Mil.
Total Assets was $1,740.0 Mil.
Property, Plant and Equipment(Net PPE) was $198.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $69.4 Mil.
Selling, General, & Admin. Expense(SGA) was $310.7 Mil.
Total Current Liabilities was $89.9 Mil.
Long-Term Debt & Capital Lease Obligation was $604.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(131.227 / 591.643) / (119.711 / 509.728)
=0.221801 / 0.234853
=0.9444

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(187.896 / 509.728) / (244.604 / 591.643)
=0.36862 / 0.413432
=0.8916

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (596.812 + 183.781) / 1681.229) / (1 - (605.291 + 198.608) / 1740.034)
=0.535701 / 0.537998
=0.9957

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=591.643 / 509.728
=1.1607

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(69.43 / (69.43 + 198.608)) / (72.583 / (72.583 + 183.781))
=0.25903 / 0.283125
=0.9149

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(313.943 / 591.643) / (310.677 / 509.728)
=0.530629 / 0.609496
=0.8706

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((606.069 + 96.304) / 1681.229) / ((604.274 + 89.932) / 1740.034)
=0.417774 / 0.398961
=1.0472

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-87.968 - -10.444 - -1.953) / 1681.229
=-0.04495

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

NeoGenomics has a M-score of -2.66 suggests that the company is unlikely to be a manipulator.


NeoGenomics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913

NeoGenomics (NeoGenomics) Headlines

From GuruFocus